{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:53:05Z","timestamp":1791247985375,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":120,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16280-z","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T09:57:10Z","timestamp":1780912630000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world effectiveness of mecapegfilgrastim for prophylaxis in patients with breast cancer receiving 2-weekly and 3-weekly chemotherapy in China"],"prefix":"10.1186","volume":"26","author":[{"given":"Yanxia","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peifen","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongsheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumin","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guifang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhangxia","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Bie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanggui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruihua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"issue":"1","key":"16280_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348.","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"16280_CR2","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1001\/jamaoncol.2017.1114","volume":"3","author":"K Patel","year":"2017","unstructured":"Patel K, West HJ. Febrile Neutropenia. JAMA Oncol. 2017;3(12):1751.","journal-title":"JAMA Oncol"},{"issue":"8","key":"16280_CR3","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1200\/JCO.2003.09.081","volume":"21","author":"ML Citron","year":"2003","unstructured":"Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741\/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003;21(8):1431\u20139.","journal-title":"J Clin Oncol"},{"issue":"9980","key":"16280_CR4","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1016\/S0140-6736(14)62048-1","volume":"385","author":"L Del Mastro","year":"2015","unstructured":"Del Mastro L, De Placido S, Bruzzi P, De Laurentiis M, Boni C, Cavazzini G, et al. Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 \u00d7 2 factorial, randomised phase 3 trial. Lancet. 2015;385(9980):1863\u201372.","journal-title":"Lancet"},{"issue":"5","key":"16280_CR5","doi-asserted-by":"publisher","first-page":"e0234058","DOI":"10.1371\/journal.pone.0234058","volume":"15","author":"Y Ding","year":"2020","unstructured":"Ding Y, Ding K, Yang H, He X, Mo W, Ding X. Does dose-dense neoadjuvant chemotherapy have clinically significant prognostic value in breast cancer? A meta-analysis of 3,724 patients. PLoS ONE. 2020;15(5):e0234058.","journal-title":"PLoS ONE"},{"issue":"2","key":"16280_CR6","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/cncr.11882","volume":"100","author":"J Crawford","year":"2004","unstructured":"Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer. 2004;100(2):228\u201337.","journal-title":"Cancer"},{"issue":"suppl 5","key":"16280_CR7","doi-asserted-by":"publisher","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","volume":"27","author":"J Klastersky","year":"2016","unstructured":"Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M, et al. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol. 2016;27(suppl 5):v111\u20138.","journal-title":"Ann Oncol"},{"issue":"5","key":"16280_CR8","doi-asserted-by":"publisher","first-page":"436","DOI":"10.6004\/jnccn.2022.0026","volume":"20","author":"EA Griffiths","year":"2022","unstructured":"Griffiths EA, Roy V, Alwan L, Bachiashvili K, Baird J, Cool R, et al. NCCN Guidelines\u00ae Insights: Hematopoietic Growth Factors, Version 1.2022. J Natl Compr Canc Netw. 2022;20(5):436\u201342.","journal-title":"J Natl Compr Canc Netw"},{"issue":"7","key":"16280_CR9","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1007\/s00520-014-2555-y","volume":"23","author":"G Kourlaba","year":"2015","unstructured":"Kourlaba G, Dimopoulos MA, Pectasides D, Skarlos DV, Gogas H, Pentheroudakis G, et al. Comparison of filgrastim and pegfilgrastim to prevent neutropenia and maintain dose intensity of adjuvant chemotherapy in patients with breast cancer. Support Care Cancer. 2015;23(7):2045\u201351.","journal-title":"Support Care Cancer"},{"issue":"2","key":"16280_CR10","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/sj.bjc.6604862","volume":"100","author":"RL Jones","year":"2009","unstructured":"Jones RL, Walsh G, Ashley S, Chua S, Agarwal R, O\u2019Brien M, et al. A randomised pilot Phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer. Br J Cancer. 2009;100(2):305\u201310.","journal-title":"Br J Cancer"},{"issue":"8","key":"16280_CR11","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.1007\/s00520-018-4572-8","volume":"27","author":"X Wang","year":"2019","unstructured":"Wang X, He Y, Wang T, Xie Y, Li J, Ouyang T, et al. Efficacy of pegfilgrastim to support neoadjuvant dose-dense epirubicin and cyclophosphamide chemotherapy in breast cancer. Support Care Cancer. 2019;27(8):3019\u201325.","journal-title":"Support Care Cancer"},{"issue":"18","key":"16280_CR12","doi-asserted-by":"publisher","first-page":"482","DOI":"10.21037\/atm.2019.07.95","volume":"7","author":"F Xu","year":"2019","unstructured":"Xu F, Zhang Y, Miao Z, Zeng X, Wu B, Cai L, et al. Efficacy and safety of mecapegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer: a randomized, multicenter, active-controlled phase III trial. Ann Transl Med. 2019;7(18):482.","journal-title":"Ann Transl Med"},{"issue":"11","key":"16280_CR13","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/S1995-7645(13)60163-7","volume":"6","author":"B Yan","year":"2013","unstructured":"Yan B, Zhang W, Lu F, Chen Z-L, Han B-H, Jiang L-Y. Safety of polyethylene glycol recombinant human granulocyte colony-stimulating factor in treating non-small cell lung cancer patients at I b stage. Asian Pac J Trop Med. 2013;6(11):912\u20135.","journal-title":"Asian Pac J Trop Med"},{"issue":"11","key":"16280_CR14","doi-asserted-by":"publisher","first-page":"426","DOI":"10.6004\/jnccn.2025.0053","volume":"23","author":"WJ Gradishar","year":"2025","unstructured":"Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, et al. NCCN Guidelines\u00ae Insights: Breast Cancer, Version 5.2025. J Natl Compr Canc Netw. 2025;23(11):426\u201336.","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"16280_CR15","doi-asserted-by":"publisher","first-page":"594","DOI":"10.6004\/jnccn.2023.0031","volume":"21","author":"WJ Gradishar","year":"2023","unstructured":"Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, et al. NCCN Guidelines\u00ae Insights: Breast Cancer, Version 4.2023. J Natl Compr Canc Netw. 2023;21(6):594\u2013608.","journal-title":"J Natl Compr Canc Netw"},{"issue":"10","key":"16280_CR16","doi-asserted-by":"publisher","first-page":"893","DOI":"10.21037\/atm-21-2449","volume":"9","author":"J Ma","year":"2021","unstructured":"Ma J, Huang H, Fu P, Xu N, Mao C, Cheng G, et al. Prophylaxis of neutropenia with mecapegfilgrastim in patients with non-myeloid malignancies: a real-world study. Ann Transl Med. 2021;9(10):893.","journal-title":"Ann Transl Med"},{"issue":"1","key":"16280_CR17","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1186\/s12885-025-14144-6","volume":"25","author":"S Qin","year":"2025","unstructured":"Qin S, Shi Y, Fu P, Xu N, Mao C, Chen Y, et al. Mecapegfilgrastim prophylaxis for neutropenia in patients with non-myeloid malignancies: A Chinese nationwide real-world study. BMC Cancer. 2025;25(1):742.","journal-title":"BMC Cancer"},{"issue":"3","key":"16280_CR18","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s00520-012-1589-2","volume":"21","author":"S Lee","year":"2013","unstructured":"Lee S, Knox A, Zeng ISL, Coomarasamy C, Blacklock H, Issa S. Primary prophylaxis with granulocyte colony-stimulating factor (GCSF) reduces the incidence of febrile neutropenia in patients with non-Hodgkin lymphoma (NHL) receiving CHOP chemotherapy treatment without adversely affecting their quality of life: cost-benefit and quality of life analysis. Support Care Cancer. 2013;21(3):841\u20136.","journal-title":"Support Care Cancer"},{"issue":"8","key":"16280_CR19","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1093\/oncolo\/oyac074","volume":"27","author":"R Boccia","year":"2022","unstructured":"Boccia R, Glaspy J, Crawford J, Aapro M. Chemotherapy-Induced Neutropenia and Febrile Neutropenia in the US: A Beast of Burden That Needs to Be Tamed? Oncologist. 2022;27(8):625\u201336.","journal-title":"Oncologist"},{"issue":"5","key":"16280_CR20","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1159\/000524984","volume":"17","author":"M Kiechle","year":"2022","unstructured":"Kiechle M, Schem C, L\u00fcftner D, Hipp J, Stetzer E, K\u00f6hler U. Prophylaxis of Neutropenia with Lipegfilgrastim in Breast Cancer Patients with Dose-Dense Chemotherapy: Results of a Noninterventional Study on Therapeutic Routine in Germany (NADENS). Breast Care (Basel). 2022;17(5):508\u201313.","journal-title":"Breast Care (Basel)"},{"issue":"7\u20138","key":"16280_CR21","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1007\/s00508-015-0917-1","volume":"128","author":"R M\u0105dry","year":"2016","unstructured":"M\u0105dry R, Pop\u0142awska L, Haslbauer F, \u0160afanda M, Ghizdavescu D, Benkovicova J, et al. Results of a prospective dose intensity and neutropenia prophylaxis evaluation programme (DIEPP) in cancer patients at risk of febrile neutropenia due to myelosuppressive chemotherapy. Wien Klin Wochenschr. 2016;128(7\u20138):238\u201347.","journal-title":"Wien Klin Wochenschr"},{"issue":"6","key":"16280_CR22","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1093\/annonc\/mdf130","volume":"13","author":"FA Holmes","year":"2002","unstructured":"Holmes FA, Jones SE, O\u2019Shaughnessy J, Vukelja S, George T, Savin M, et al. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann Oncol. 2002;13(6):903\u20139.","journal-title":"Ann Oncol"},{"issue":"1","key":"16280_CR23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/annonc\/mdg019","volume":"14","author":"MD Green","year":"2003","unstructured":"Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol. 2003;14(1):29\u201335.","journal-title":"Ann Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16280-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16280-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16280-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:07:41Z","timestamp":1791245261000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16280-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16280"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16280-z","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"assertion":[{"value":"13 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was approved by the ethics committees of Harbin Institute of Hematology and Oncology (No. 2019-006) and was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not Applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1193"}}